Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Total Valuation
Protagonist Therapeutics has a market cap or net worth of $3.37B. The enterprise value is $412.96M.
Market Cap$3.37B
Enterprise Value$412.96M
Share Statistics
Protagonist Therapeutics has 61,981,956 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,981,956
Owned by Insiders1.72%
Owned by Institutions50.31%
Financial Efficiency
Protagonist Therapeutics’s return on equity (ROE) is 0.41 and return on invested capital (ROIC) is 35.69%.
Return on Equity (ROE)0.41
Return on Assets (ROA)0.37
Return on Invested Capital (ROIC)35.69%
Return on Capital Employed (ROCE)0.36
Revenue Per Employee3.50M
Profits Per Employee2.22M
Employee Count124
Asset Turnover0.58
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagonist Therapeutics is 8.64. Protagonist Therapeutics’s PEG ratio is 0.88.
PE Ratio8.64
PS Ratio0.00
PB Ratio-1.00
Price to Fair Value3.52
Price to FCF-4.91
Price to Operating Cash Flow-4.95
PEG Ratio0.88
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 434.43M and earned 275.19M in profits. Earnings per share was 4.47.
Revenue434.43M
Gross Profit431.47M
Operating Income252.84M
Pretax Income279.41M
Net Income275.19M
EBITDA252.84M
Earnings Per Share (EPS)4.47
Cash Flow
In the last 12 months, operating cash flow was 336.94M and capital expenditures -1.66M, giving a free cash flow of 335.29M billion.
Operating Cash Flow336.94M
Free Cash Flow335.29M
Free Cash Flow per Share5.41
Dividends & Yields
Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.84
52-Week Price Change60.72%
50-Day Moving Average48.63
200-Day Moving Average44.55
Relative Strength Index (RSI)66.11
Average Volume (3m)868.87K
Important Dates
Protagonist Therapeutics upcoming earnings date is Jul 31, 2025, After Close (Confirmed).
Last Earnings DateApr 30, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Protagonist Therapeutics as a current ratio of 12.48, with Debt / Equity ratio of -0.68%
Current Ratio12.48
Quick Ratio12.48
Debt to Market Cap<0.01
Net Debt to EBITDA-0.34
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagonist Therapeutics has paid 4.22M in taxes.
Income Tax4.22M
Effective Tax Rate0.02
Enterprise Valuation
Protagonist Therapeutics EV to EBITDA ratio is 9.06, with an EV/FCF ratio of 12.53.
EV to Sales5.27
EV to EBITDA9.06
EV to Free Cash Flow12.53
EV to Operating Cash Flow12.44
Balance Sheet
Protagonist Therapeutics has $574.36M in cash and marketable securities with $11.36M in debt, giving a net cash position of -$563.00M billion.
Cash & Marketable Securities$574.36M
Total Debt$11.36M
Net Cash-$563.00M
Net Cash Per Share-$9.08
Tangible Book Value Per Share$10.97
Margins
Gross margin is 96.12%, with operating margin of 58.20%, and net profit margin of 63.34%.
Gross Margin96.12%
Operating Margin58.20%
Pretax Margin64.32%
Net Profit Margin63.34%
EBITDA Margin58.20%
EBIT Margin58.20%
Analyst Forecast
The average price target for Protagonist Therapeutics is $70.63, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$70.63
Price Target Upside27.91% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-34.02%
EPS Growth Forecast-65.83%